Experimental group:Telitacicept
Sponsors
The Second Affiliated Hospital of Kunming Medical University, Qilu Hospital of Shandong University, Shandong Provincial Hospital, Peking Union Medical College Hospital, Chinese PLA General Hospital
Conditions
Generalized myasthenia gravisIgA NephropathyMembranous nephropathyPrimary Immune ThrombocytopeniaPrimary Membranous NephropathyRheumatoid Arthritisinflammatory myopathy
Early Phase 1
Phase 4
Efficacy and safety analysis of Tetrasip in refractory primary immune thrombocytopenia
Active, not recruitingChiCTR2100051890
Start: 2021-11-01Updated: 2022-06-27
Clinical study on the efficacy and safety of tatacept in the treatment of idiopathic membranous nephropathy
RecruitingChiCTR2200055179
Start: 2022-01-03Updated: 2023-01-16
Efficacy and Safety of Telitacicept in Patients with IgA Nephropathy with Unsatisfactory Response to Traditional Therapy
Active, not recruitingChiCTR2200064790
Start: 2022-11-01Updated: 2023-05-15
Study on the therapeutic efficacy and safety of Telitacicept in the treatment of relapsed and refractory inflammatory myopathy
Active, not recruitingChiCTR2300070348
Start: 2023-04-10Updated: 2023-06-04
Unknown Phase
The efficacy and safety of treatment with telitacicept in active rheumatoid arthritis: a real-world study
Active, not recruitingChiCTR2500101014
Start: 2025-04-30Updated: 2025-04-21
Efficacy and Safety of Telitacicept in New-Onset Generalized Myasthenia Gravis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Active, not recruitingChiCTR2600127659
Start: 2026-07-04Updated: 2026-07-13